Benhamou D, Girault C, Faure C, Portier F, Muir J F
Service de Pneumologie, CHU de Rouen (Hôpital de Boisguillaume), France.
Chest. 1992 Sep;102(3):912-7. doi: 10.1378/chest.102.3.912.
Nasal mask ventilation (NMV) has been used successfully in chronic restrictive respiratory failure and more recently in acute exacerbations of chronic obstructive pulmonary disease (COPD). This study aimed to evaluate the possible role of NMV in acute respiratory failure (ARF) episodes when mechanical ventilation with endotracheal intubation is questionable. Thirty patients (age, 76 +/- 8.1 years) were treated by NMV during ARF episodes (COPD, 20; other chronic respiratory failure [CRF], 5; chronic heart failure [CHF], 4). All patients were hypoxemic (PaO2, 5.85 +/- 1.62 kPa) and hypercapnic (PaCO2, 8.63 +/- 1.89 kPa) with respiratory acidosis (pH, 7.29 +/- 0.08). In all cases, clinical or physiologic parameters indicated the need for mechanical ventilation, but endotracheal intubation was either not applied because of the age and the physiologic condition of the patients (17 cases) or was postponed (13 cases). NMV was performed using a volume-cycled ventilator and a customized nasal mask. Ventilation was continuous during the first 12 hours and the following nights and was then intermittent during the day. Twenty-one patients improved clinically, within a few hours. Progressive correction of arterial blood gases was observed: PaO2 increased during the first hour, but PaCO2 decreased more slowly. Eighteen patients were able to be successfully weaned from NMV. Twelve patients failed to improve despite NMV: eight of them died and four required endotracheal intubation. There was no difference in the success rate between patients in whom endotracheal ventilation was contraindicated or postponed. Clinical tolerance was satisfactory in 23 patients and poor in seven patients. A return to the respiratory condition was observed in the surviving patients with subsequent discharge from hospital. NMV therefore successfully treated respiratory distress initially in 60 percent of the 30 patients. These results suggest that NMV could be a possible alternative in the treatment of ARF, even in very ill patients, when endotracheal ventilation is controversial or not immediately required.
鼻罩通气(NMV)已成功应用于慢性限制性呼吸衰竭,最近也用于慢性阻塞性肺疾病(COPD)急性加重期。本研究旨在评估当气管插管机械通气存在疑问时,NMV在急性呼吸衰竭(ARF)发作中的可能作用。30例患者(年龄76±8.1岁)在ARF发作期间接受NMV治疗(COPD患者20例;其他慢性呼吸衰竭[CRF]患者5例;慢性心力衰竭[CHF]患者4例)。所有患者均存在低氧血症(动脉血氧分压[PaO2]为5.85±1.62 kPa)和高碳酸血症(动脉血二氧化碳分压[PaCO2]为8.63±1.89 kPa),伴有呼吸性酸中毒(pH值为7.29±0.08)。在所有病例中,临床或生理参数均表明需要机械通气,但由于患者年龄和生理状况,17例患者未进行气管插管,13例患者气管插管被推迟。使用容量控制通气机和定制鼻罩进行NMV。最初12小时及随后的夜间通气持续进行,白天则为间歇通气。21例患者在数小时内临床症状改善。观察到动脉血气逐渐得到纠正:PaO2在第1小时升高,但PaCO2下降较慢。18例患者成功撤机。12例患者尽管接受了NMV治疗仍未改善:其中8例死亡,4例需要气管插管。气管插管禁忌或推迟的患者成功率无差异。23例患者临床耐受性良好,7例患者较差。存活患者出院时呼吸状况恢复。因此,NMV成功地初步治疗了30例患者中60%的呼吸窘迫。这些结果表明,当气管插管通气存在争议或并非立即需要时,NMV可能是治疗ARF的一种替代方法,即使是病情非常严重的患者。